Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CISD1 | Q9NZ45 | 8/20 | 0.49 |
| ▸ | KDM6B | O15054 | 2/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2426202 | 0.90 | CISD1 (0.52) | CISD1KDM6BKDM4CHCAR3PLK1 | |
| SCHEMBL2431511 | 0.84 | CISD1 (0.51) | CISD1KDM6BKDM4CHCAR3KDM4E | |
| SCHEMBL2434508 | 0.83 | CISD1 (0.34) | CISD1HSP90AA1HSP90AB1KDM4EALDH1A1 | |
| SCHEMBL3980322 | 0.82 | HSP90AA1 (0.40) | CISD1KDM4CHSP90AA1HSP90AB1 | |
| SCHEMBL3973224 | 0.81 | CISD1 (0.36) | CISD1KDM6BKDM4CHSP90AA1HSP90AB1 | |
| SCHEMBL3980350 | 0.81 | HSP90AA1 (0.35) | CISD1HSP90AA1HSP90AB1KDM4EALDH1A1 | |
| SCHEMBL4010874 | 0.81 | GUCY1A1 (0.40) | CISD1KDM6BKDM4CHSP90AA1HSP90AB1 | |
| SCHEMBL2428070 | 0.81 | MEN1 (0.47) | CISD1KDM6BKDM4CHCAR3MAPK14 | |
| SCHEMBL2422460 | 0.81 | JAK2 (0.40) | CISD1HSP90AA1HSP90AB1 | |
| SCHEMBL3973544 | 0.80 | HSP90AA1 (0.39) | CISD1HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012956-B2 | Tropane compounds | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012956-B2 | Tropane compounds | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012956-B2 | Tropane compounds | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| EP-2074120-B1 | TROPANE COMPOUNDS | EXELIXIS INC (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-2074120-A1 | TROPANE COMPOUNDS | Exelixis, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20090163471-A1 | Tropane compounds | EXELIXIS, INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090163471-A1 | Tropane compounds | EXELIXIS, INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090163471-A1 | Tropane compounds | EXELIXIS, INC. | 2009-06-25 | — | — | US | disclosed |
| WO-2009055077-A1 | TROPANE COMPOUNDS | EXELIXIS, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163471-A1 | Tropane compounds | ADRA1B, ADRA2B, ADRB2 | CISD1 4213/4885KDM6B 2369/4885KDM4C 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.